The other shoe that analysts have been talking about for a while now dropped today when Eli Lilly revealed that its Alzheimer drug, solanezumab, missed both its primary endpoints in a Phase III trial. Lilly's Lechleiter had at one time been touting this as an example of the internal R&D pipeline drugs that Lilly is expecting to lead it out of the wilderness.
He had backed off solanezumab as having to be the "saviour" though in the past few months when it became apparent that the drug would be a long shot to achieve it's clinical targets. This was largely apparent as Pfizer's similar drug bapineuzumab failed earlier this year.
Lechleiter is not giving up yet though as he said their analysis shows the drug may be showing a positive trend in slowing cognitive decline in patients with mild-to-moderate disease. We'll see about that John.
Posted by Bruce Lehr Aug 24th 2012.